Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...